ASH 2023 | Dara-RVd in the treatment of HR-SMM: an ongoing Phase II trial
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses an ongoing Phase II trial investigating the efficacy of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) in the treatment of high-risk smoldering multiple myeloma (HR-SMM). The trial’s endpoint is measurable residual disease (MRD) negativity, which will guide patients’ discontinuation of treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Janssen, Oncopeptides, Amgen, Novartis, GlaxoSmithKline, The Binding Site, Window Therapeutics, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Huron Consulting, Takeda, Aptitude Health, Bristol-Myers Squibb; Honoraria: AbbVie, 10x Genomics, Janssen, Novartis, GlaxoSmithKline, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Takeda, Vor Biopharma, Adaptive, Bristol-Myers Squibb; Research Funding: Novartis; Ended employment in the past 24 months: Vor Biopharma; Speakers Bureau: Vor Biopharma; Spouse is Chief Medical Officer and holds equity in the company: Disc Medicine.
